New Zealand tries visa waiver to Chinese citizens travelling from Australia
Tourists take in the view of Auckland, New Zealand, after the rain from atop Mt Eden, a dormant volcano also know by its Maori name, Maungawhau, on Oct 5, 2024. - Photo: AP
WELLINGTON: (Bernama-Xinhua) The New Zealand government announced a visa waiver policy on Sunday (June 15) for Chinese citizens travelling from Australia, Xinhua reported.
According to Immigration New Zealand, starting November 2025, New Zealand will be trialling visa waiver status for Chinese passport holders travelling from Australia with a valid Australian visitor, work, student or family visa, allowing them to visit New Zealand for up to three months with a New Zealand Electronic Travel Authority (NZeTA) rather than applying for a visa.
This does not include people transiting through Australia, and applicants will still need to meet the criteria for an NZeTA.
Sunday's visa waiver announcement is a trial policy for 12 months and is believed to boost New Zealand's attractiveness as a destination for Chinese tourists. - Bernama-Xinhua
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
WST Deadline: WST Investors with Losses in Excess of $100K Have Opportunity to West Pharmaceutical Services, Inc. Securities Fraud Lawsuit
NEW YORK, June 15, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the 'Class Period'), of the important July 7, 2025 lead plaintiff deadline. So what: If you purchased West Pharmaceutical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the West Pharmaceutical class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products ('HVP') portfolio; (2) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West's profit margins due to operational inefficiencies; (3) these margin pressures created the risk of costly restructuring activities, including West's exit from continuous glucose monitoring ('CGM') contracts with long-standing customers; and (4) as a result of the foregoing, defendants' positive statements about West's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the West Pharmaceutical class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Kim, Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827case@
The Star
3 hours ago
- The Star
Israel's annual inflation down to 3.1 pct in May, lowest in nearly year
JERUSALEM, June 15 (Xinhua) -- Israel's 12-month inflation rate decreased to 3.1 percent in May, down from 3.6 percent in April, according to data issued Sunday by the Central Bureau of Statistics. This marks the lowest 12-month inflation figure since June 2024, when it stood at 2.9 percent. The decline brings inflation closer to the government's target range of 1 to 3 percent. Analysts said the decline may lead the central bank to reduce its base interest rate, which has remained unchanged at 4.5 percent since January 2024. The monthly consumer price index (CPI), a key measure of inflation, decreased by 0.3 percent in May. This followed a 1.1 percent rise in April, which was the highest monthly increase since July 2022. May's drop was driven mainly by a 7.9 percent decline in airfare prices, part of a 2.4 percent fall in the broader transport and communication category.
The Star
4 hours ago
- The Star
UAE economy grows 4 pct in 2024, driven by non-oil sectors
DUBAI, June 15 (Xinhua) -- The United Arab Emirates (UAE) recorded a 4 percent real GDP growth in 2024, reaching 1.77 trillion dirhams (about 482 billion U.S. dollars), fueled primarily by robust expansion in non-oil sectors, the Ministry of Economy announced on Sunday. Non-oil activities surged by 5 percent to 1.34 trillion dirhams, accounting for 75.5 percent of total GDP. In contrast, the oil sector contributed 434 billion dirhams. Abdulla bin Touq Al Marri, UAE's economy minister, said the latest figures highlight progress toward transitioning to a knowledge-based, sustainable economy. He attributed the performance to modern economic policies centered on innovation, technology, and business environment development. "The UAE continues to move steadily toward the goals of the 'We the UAE 2031' vision, which aims to raise GDP to 3 trillion dirhams and reinforce the country's position as a global hub for the new economy," he added. Several key sectors recorded notable growth during the year. The transport and storage sector led the way with a 9.6 percent increase, driven by a 10 percent year-on-year rise in passenger traffic in airports, which handled 147.8 million travelers. The construction sector expanded by 8.4 percent due to increased investment in infrastructure, while financial and insurance activities grew by 7 percent, hospitality and food services by 5.7 percent, and real estate by 4.8 percent. In terms of contribution to non-oil GDP, the trade sector ranked first with 16.8 percent, followed by manufacturing (13.5 percent), financial and insurance activities (13.2 percent), construction (11.7 percent), and real estate (7.8 percent). Commenting on the data, Mazen Al-Obaid, an economics professor at UAE University, told Xinhua that the growth reflects the effectiveness of government efforts to build a diversified economy based on advanced productive and service sectors. "What distinguishes this growth is that it is driven by real economic activity, not just temporary fiscal stimulus, which enhances the country's resilience to global market volatility and energy price fluctuations," he noted. He added that the UAE's focus on innovation, digital infrastructure, and investment climate makes it a competitive economic model, urging continued investment in national talent and high-value industries to ensure sustainable growth.
